Winner Medical(SZ:300888) Zheng Quan Zhi Xing·2025-08-21 12:13Core Viewpoint - The company has adjusted the grant price of its 2024 restricted stock incentive plan due to the implementation of equity distribution, lowering the price from 15.39 CNY per share to 14.69 CNY per share [1][4]. Group 1: Approval Process - The company held the fourth board meeting and the fourth supervisory board meeting on August 20, 2025, where the adjustment of the grant price was approved [1]. - The supervisory board confirmed that the individuals included in the incentive plan met the necessary legal and regulatory conditions [2]. Group 2: Reasons for Price Adjustment - The adjustment was made following a cash dividend distribution totaling 145,582,452 CNY (including tax), with no capital reserve conversion or stock dividends [2][3]. - The company distributed a cash dividend of 6.50 CNY per 10 shares (including tax) for the year 2024, amounting to a total of 378,514,375.20 CNY (including tax) [3]. Group 3: Adjustment Methodology - The adjustment formula for the grant price is defined as P = P0 - V, where P0 is the original grant price, V is the dividend per share, and P is the adjusted grant price [3]. - The adjusted grant price calculation is as follows: 15.39 CNY - 0.25 CNY - 0.45 CNY = 14.69 CNY per share [4]. Group 4: Impact of Adjustment - The adjustment complies with relevant laws and regulations and will not materially affect the company's financial status or operational results [5]. - The adjustment has been authorized within the scope of the board's powers and does not require further shareholder approval [5]. Group 5: Legal Opinion - The legal opinion from Beijing Zhonglun (Shenzhen) Law Firm confirms that the adjustment of the grant price has obtained necessary approvals and complies with relevant regulations [5].